{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T10:45:55Z","timestamp":1770461155266,"version":"3.49.0"},"reference-count":6,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.anai.2022.07.023","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T01:57:06Z","timestamp":1658973426000},"page":"642-643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Type 2 biologics reduce cumulative steroid exposure in aspirin-exacerbated respiratory disease"],"prefix":"10.1016","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2682-7957","authenticated-orcid":false,"given":"Yasamin","family":"Ghiasi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Wangberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha R. Spierling","family":"Bagsic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.anai.2022.07.023_bib0001","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1081-1206(10)62084-4","article-title":"The natural history and clinical characteristics of aspirin-exacerbated respiratory disease","volume":"89","author":"Berges-Gimeno","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2022.07.023_bib0002","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2022.07.023_bib0003","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","article-title":"Oral corticosteroid exposure and adverse effects in asthmatic patients","volume":"141","author":"Sullivan","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2022.07.023_bib0004","doi-asserted-by":"crossref","unstructured":"Kroes JA, Zielhuis SW, De Jong K, Hashimoto S, Sont JK, Zielhuis SW, et al. Cumulative corticosteroid sparing effect of anti-interleukin-5\/5Ra in eosinophilic asthma [e-pub ahead of print]. Eur Respir J. doi.org\/10.1183\/13993003.02983-2021, Accessed May 22, 2022.","DOI":"10.1183\/13993003.02983-2021"},{"issue":"2","key":"10.1016\/j.anai.2022.07.023_bib0005","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0002-9343(77)90233-9","article-title":"Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function","volume":"63","author":"Meikle","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.anai.2022.07.023_bib0006","series-title":"Healthcare Cost and Utilization Project (HCUP) statistical briefs [Internet]","article-title":"Origin of adverse drug events in U.S. Hospitals, 2011","volume":"158","author":"Weiss","year":"2013"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622006172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622006172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:29:41Z","timestamp":1761053381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120622006172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":6,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1081120622006172"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2022.07.023","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type 2 biologics reduce cumulative steroid exposure in aspirin-exacerbated respiratory disease","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2022.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}